Exact Mass: 481.2747644

Exact Mass Matches: 481.2747644

Found 500 metabolites which its exact mass value is equals to given mass value 481.2747644, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

LysoPE(18:0/0:0)

(2-aminoethoxy)[(2R)-2-hydroxy-3-(octadecanoyloxy)propoxy]phosphinic acid

C23H48NO7P (481.3168228)

LysoPE(18:0/0:0) or LPE(18:0/0:0) is a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms. [HMDB] LysoPE(18:0/0:0) or LPE(18:0/0:0) is a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms.

N-Acetyl-leukotriene E4

[5S-[5R*,6S*(s*),7E,9E,11Z,14Z]]-6-[[2-(acetylamino)-2-carboxyethyl]thio]-5-hydroxy-7,9,11,14-eicosatetraenoic acid

C25H39NO6S (481.24979540000004)

N acetyl LTE4 is a minor metabolite of Leukotriene E4 in normal human subjects. (PMID: 2174886) [HMDB] N acetyl LTE4 is a minor metabolite of Leukotriene E4 in normal human subjects. (PMID: 2174886).

JI-20A

Antibiotic JI-20A

C19H39N5O9 (481.2747644)

D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D005839 - Gentamicins

LysoPE(0:0/18:0)

(2-aminoethoxy)[(2R)-3-hydroxy-2-(octadecanoyloxy)propoxy]phosphinic acid

C23H48NO7P (481.3168228)

LysoPE(0:0/18:0) or LPE(0:0/18:0) is a lysophospholipid. The term lysophospholipid (LPL) refers to any phospholipid that is missing one of its two O-acyl chains. Thus, LPLs have a free alcohol in either the sn-1 or sn-2 position. The prefix lyso- comes from the fact that lysophospholipids were originally found to be hemolytic however it is now used to refer generally to phospholipids missing an acyl chain. LPLs are usually the result of phospholipase A-type enzymatic activity on regular phospholipids such as phosphatidylcholine or phosphatidic acid, although they can also be generated by the acylation of glycerophospholipids or the phosphorylation of monoacylglycerols. Some LPLs serve important signaling functions such as lysophosphatidic acid. Lysophosphatidylethanolamines (LPEs) can function as plant growth regulators with several diverse uses. (LPEs) are approved for outdoor agricultural use to accelerate ripening and improve the quality of fresh produce. They are also approved for indoor use to preserve stored crops and commercial cut flowers. As a breakdown product of phosphatidylethanolamine (PE), LPE is present in cells of all organisms.

LysoPC(15:0/0:0)

(2-{[(2R)-2-hydroxy-3-(pentadecanoyloxy)propyl phosphono]oxy}ethyl)trimethylazanium

C23H48NO7P (481.3168228)

LysoPC(15:0) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(15:0), in particular, consists of one chain of pentadecanoic acid at the C-1 position. The pentadecanoic acid moiety is derived from dairy products and milk fat. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins. [HMDB] LysoPC(15:0) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. Lysophosphatidylcholines can have different combinations of fatty acids of varying lengths and saturation attached at the C-1 (sn-1) position. Fatty acids containing 16, 18 and 20 carbons are the most common. LysoPC(15:0), in particular, consists of one chain of pentadecanoic acid at the C-1 position. The pentadecanoic acid moiety is derived from dairy products and milk fat. Lysophosphatidylcholine is found in small amounts in most tissues. It is formed by hydrolysis of phosphatidylcholine by the enzyme phospholipase A2, as part of the de-acylation/re-acylation cycle that controls its overall molecular species composition. It can also be formed inadvertently during extraction of lipids from tissues if the phospholipase is activated by careless handling. In blood plasma significant amounts of lysophosphatidylcholine are formed by a specific enzyme system, lecithin:cholesterol acyltransferase (LCAT), which is secreted from the liver. The enzyme catalyzes the transfer of the fatty acids of position sn-2 of phosphatidylcholine to the free cholesterol in plasma, with formation of cholesterol esters and lysophosphatidylcholine. Lysophospholipids have a role in lipid signaling by acting on lysophospholipid receptors (LPL-R). LPL-Rs are members of the G protein-coupled receptor family of integral membrane proteins.

7,14-Dihydroxyoctadeca-4,8,10,12-tetraenedioylcarnitine

3-[(17-carboxy-7,14-dihydroxyheptadeca-4,8,10,12-tetraenoyl)oxy]-4-(trimethylazaniumyl)butanoate

C25H39NO8 (481.2675534)

7,14-dihydroxyoctadeca-4,8,10,12-tetraenedioylcarnitine is an acylcarnitine. More specifically, it is an 7,14-dihydroxyoctadeca-4,8,10,12-tetraenedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7,14-dihydroxyoctadeca-4,8,10,12-tetraenedioylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 7,14-dihydroxyoctadeca-4,8,10,12-tetraenedioylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

dihydrocytochalasin B

16-benzyl-5,13-dihydroxy-9,15-dimethyl-14-methylidene-2H,3H,4H,5H,6H,7H,8H,9H,10H,13H,14H,15H,15aH,16H,17H,18H,18bH-oxacyclotetradeca[3,2-e]isoindole-2,18-dione

C29H39NO5 (481.2828084)

Dofequidar

1-{4-[2-hydroxy-3-(quinolin-5-yloxy)propyl]piperazin-1-yl}-2,2-diphenylethan-1-one

C30H31N3O3 (481.23652960000004)

N-acetyl Leukotriene E4

6-({2-carboxy-2-[(1-hydroxyethylidene)amino]ethyl}sulphanyl)-5-hydroxyicosa-7,9,11,14-tetraenoic acid

C25H39NO6S (481.24979540000004)

Palmitoyl Ara-C

N-{1-[3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxo-1,2-dihydropyrimidin-4-yl}hexadecanamide

C25H43N3O6 (481.31516980000004)

Delphatine

C26H43NO7 (481.30393680000003)

18-Demethylpubescenine

18-O-Demethylpubescenine

C25H39NO8 (481.2675534)

2-[3alpha-Hydroxy-5beta-cholen-(8(14))-oyl-(24)-amino]-aethansulfonsaeure-(1)|2-[3alpha-hydroxy-5beta-cholen-(8(14))-oyl-(24)-amino]-ethanesulfonic acid-(1)|N-[3alpha-[Hydroxy-5beta-cholen-(8(14))-oyl-(24)]-taurin

2-[3alpha-Hydroxy-5beta-cholen-(8(14))-oyl-(24)-amino]-aethansulfonsaeure-(1)|2-[3alpha-hydroxy-5beta-cholen-(8(14))-oyl-(24)-amino]-ethanesulfonic acid-(1)|N-[3alpha-[Hydroxy-5beta-cholen-(8(14))-oyl-(24)]-taurin

C26H43NO5S (481.2861788000001)

Browniine

C26H43NO7 (481.30393680000003)

14-O-Acetyltakaosamine

C25H39NO8 (481.2675534)

C28H35NO6

C28H35NO6 (481.24642500000004)

citrinadin B

C28H39N3O4 (481.2940414)

8-Methyllycoctonine

C26H43NO7 (481.30393680000003)

Ala Tyr Thr Lys

(2S)-6-amino-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-(4-hydroxyphenyl)propanamido]-3-hydroxybutanamido]hexanoic acid

C22H35N5O7 (481.25363600000003)

Ala Thr Tyr Lys

(2S)-6-amino-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-aminopropanamido]-3-hydroxybutanamido]-3-(4-hydroxyphenyl)propanamido]hexanoic acid

C22H35N5O7 (481.25363600000003)

Phe Thr Ser Lys

(2S)-6-amino-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-3-phenylpropanamido]-3-hydroxybutanamido]-3-hydroxypropanamido]hexanoic acid

C22H35N5O7 (481.25363600000003)

Phosphatidylethanolamine lyso 18:0

C23H48NO7P (481.3168228)

1-pentadecanoyl-2-hydroxy-sn-glycero-3-phosphocholine

C23H48NO7P (481.3168228)

CONFIDENCE standard compound; INTERNAL_ID 259

(2-aminoethoxy)[2-hydroxy-3-(octadecanoyloxy)propoxy]phosphinic acid

C23H48NO7P (481.3168228)

LPC 15:0-d5

C23H48NO7P (481.3168228)

Ala His Arg Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-(1H-imidazol-4-yl)propanamido]-5-carbamimidamidopentanamido]-3-methylbutanoic acid

C20H35N9O5 (481.27610200000004)

Ala His Val Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-methylbutanamido]-5-carbamimidamidopentanoic acid

C20H35N9O5 (481.27610200000004)

Ala Lys Thr Tyr

(2S)-2-[(2S,3R)-2-[(2S)-6-amino-2-[(2S)-2-aminopropanamido]hexanamido]-3-hydroxybutanamido]-3-(4-hydroxyphenyl)propanoic acid

C22H35N5O7 (481.25363600000003)

Ala Lys Tyr Thr

(2S,3R)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-aminopropanamido]hexanamido]-3-(4-hydroxyphenyl)propanamido]-3-hydroxybutanoic acid

C22H35N5O7 (481.25363600000003)

Ala Arg His Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-5-carbamimidamidopentanamido]-3-(1H-imidazol-4-yl)propanamido]-3-methylbutanoic acid

C20H35N9O5 (481.27610200000004)

Ala Arg Val His

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-5-carbamimidamidopentanamido]-3-methylbutanamido]-3-(1H-imidazol-4-yl)propanoic acid

C20H35N9O5 (481.27610200000004)

Ala Thr Lys Tyr

(2S)-2-[(2S)-6-amino-2-[(2S,3R)-2-[(2S)-2-aminopropanamido]-3-hydroxybutanamido]hexanamido]-3-(4-hydroxyphenyl)propanoic acid

C22H35N5O7 (481.25363600000003)

Ala Val His Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-methylbutanamido]-3-(1H-imidazol-4-yl)propanamido]-5-carbamimidamidopentanoic acid

C20H35N9O5 (481.27610200000004)

Ala Val Arg His

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-methylbutanamido]-5-carbamimidamidopentanamido]-3-(1H-imidazol-4-yl)propanoic acid

C20H35N9O5 (481.27610200000004)

Ala Tyr Lys Thr

(2S,3R)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-(4-hydroxyphenyl)propanamido]hexanamido]-3-hydroxybutanoic acid

C22H35N5O7 (481.25363600000003)

N-Desmethylmibefradil

C28H36FN3O3 (481.27405580000004)

Phe Gly Lys Met

(2S)-2-[(2S)-6-amino-2-{2-[(2S)-2-amino-3-phenylpropanamido]acetamido}hexanamido]-4-(methylsulfanyl)butanoic acid

C22H35N5O5S (481.23587800000007)

Phe Gly Met Lys

(2S)-6-amino-2-[(2S)-2-{2-[(2S)-2-amino-3-phenylpropanamido]acetamido}-4-(methylsulfanyl)butanamido]hexanoic acid

C22H35N5O5S (481.23587800000007)

Phe Lys Gly Met

(2S)-2-{2-[(2S)-6-amino-2-[(2S)-2-amino-3-phenylpropanamido]hexanamido]acetamido}-4-(methylsulfanyl)butanoic acid

C22H35N5O5S (481.23587800000007)

Phe Lys Met Gly

2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-phenylpropanamido]hexanamido]-4-(methylsulfanyl)butanamido]acetic acid

C22H35N5O5S (481.23587800000007)

Phe Lys Ser Thr

(2S,3R)-2-[(2S)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-phenylpropanamido]hexanamido]-3-hydroxypropanamido]-3-hydroxybutanoic acid

C22H35N5O7 (481.25363600000003)

Phe Lys Thr Ser

(2S)-2-[(2S,3R)-2-[(2S)-6-amino-2-[(2S)-2-amino-3-phenylpropanamido]hexanamido]-3-hydroxybutanamido]-3-hydroxypropanoic acid

C22H35N5O7 (481.25363600000003)

Phe Met Gly Lys

(2S)-6-amino-2-{2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-4-(methylsulfanyl)butanamido]acetamido}hexanoic acid

C22H35N5O5S (481.23587800000007)

Phe Met Lys Gly

2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-4-(methylsulfanyl)butanamido]hexanamido]acetic acid

C22H35N5O5S (481.23587800000007)

Phe Ser Lys Thr

(2S,3R)-2-[(2S)-6-amino-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-hydroxypropanamido]hexanamido]-3-hydroxybutanoic acid

C22H35N5O7 (481.25363600000003)

Phe Ser Thr Lys

(2S)-6-amino-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-hydroxypropanamido]-3-hydroxybutanamido]hexanoic acid

C22H35N5O7 (481.25363600000003)

Phe Thr Lys Ser

(2S)-2-[(2S)-6-amino-2-[(2S,3R)-2-[(2S)-2-amino-3-phenylpropanamido]-3-hydroxybutanamido]hexanamido]-3-hydroxypropanoic acid

C22H35N5O7 (481.25363600000003)

Gly Phe Lys Met

(2S)-2-[(2S)-6-amino-2-[(2S)-2-(2-aminoacetamido)-3-phenylpropanamido]hexanamido]-4-(methylsulfanyl)butanoic acid

C22H35N5O5S (481.23587800000007)

Gly Phe Met Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-phenylpropanamido]-4-(methylsulfanyl)butanamido]hexanoic acid

C22H35N5O5S (481.23587800000007)

Gly His Ile Arg

(2S)-2-[(2S,3S)-2-[(2S)-2-(2-aminoacetamido)-3-(1H-imidazol-4-yl)propanamido]-3-methylpentanamido]-5-carbamimidamidopentanoic acid

C20H35N9O5 (481.27610200000004)

Gly His Leu Arg

(2S)-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-(1H-imidazol-4-yl)propanamido]-4-methylpentanamido]-5-carbamimidamidopentanoic acid

C20H35N9O5 (481.27610200000004)

Gly His Arg Ile

(2S,3S)-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-(1H-imidazol-4-yl)propanamido]-5-carbamimidamidopentanamido]-3-methylpentanoic acid

C20H35N9O5 (481.27610200000004)

Gly His Arg Leu

(2S)-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-(1H-imidazol-4-yl)propanamido]-5-carbamimidamidopentanamido]-4-methylpentanoic acid

C20H35N9O5 (481.27610200000004)

Gly Ile His Arg

(2S)-2-[(2S)-2-[(2S,3S)-2-(2-aminoacetamido)-3-methylpentanamido]-3-(1H-imidazol-4-yl)propanamido]-5-carbamimidamidopentanoic acid

C20H35N9O5 (481.27610200000004)

Gly Ile Arg His

(2S)-2-[(2S)-2-[(2S,3S)-2-(2-aminoacetamido)-3-methylpentanamido]-5-carbamimidamidopentanamido]-3-(1H-imidazol-4-yl)propanoic acid

C20H35N9O5 (481.27610200000004)

Gly Lys Phe Met

(2S)-2-[(2S)-2-[(2S)-6-amino-2-(2-aminoacetamido)hexanamido]-3-phenylpropanamido]-4-(methylsulfanyl)butanoic acid

C22H35N5O5S (481.23587800000007)

Gly Lys Met Phe

(2S)-2-[(2S)-2-[(2S)-6-amino-2-(2-aminoacetamido)hexanamido]-4-(methylsulfanyl)butanamido]-3-phenylpropanoic acid

C22H35N5O5S (481.23587800000007)

Gly Leu His Arg

(2S)-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-4-methylpentanamido]-3-(1H-imidazol-4-yl)propanamido]-5-carbamimidamidopentanoic acid

C20H35N9O5 (481.27610200000004)

Gly Leu Arg His

(2S)-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-4-methylpentanamido]-5-carbamimidamidopentanamido]-3-(1H-imidazol-4-yl)propanoic acid

C20H35N9O5 (481.27610200000004)

Gly Met Phe Lys

(2S)-6-amino-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-4-(methylsulfanyl)butanamido]-3-phenylpropanamido]hexanoic acid

C22H35N5O5S (481.23587800000007)

Gly Met Lys Phe

(2S)-2-[(2S)-6-amino-2-[(2S)-2-(2-aminoacetamido)-4-(methylsulfanyl)butanamido]hexanamido]-3-phenylpropanoic acid

C22H35N5O5S (481.23587800000007)

Gly Arg His Ile

(2S,3S)-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-5-carbamimidamidopentanamido]-3-(1H-imidazol-4-yl)propanamido]-3-methylpentanoic acid

C20H35N9O5 (481.27610200000004)

Gly Arg His Leu

(2S)-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-5-carbamimidamidopentanamido]-3-(1H-imidazol-4-yl)propanamido]-4-methylpentanoic acid

C20H35N9O5 (481.27610200000004)

Gly Arg Ile His

(2S)-2-[(2S,3S)-2-[(2S)-2-(2-aminoacetamido)-5-carbamimidamidopentanamido]-3-methylpentanamido]-3-(1H-imidazol-4-yl)propanoic acid

C20H35N9O5 (481.27610200000004)

Gly Arg Leu His

(2S)-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-5-carbamimidamidopentanamido]-4-methylpentanamido]-3-(1H-imidazol-4-yl)propanoic acid

C20H35N9O5 (481.27610200000004)

His Ala Arg Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]propanamido]-5-carbamimidamidopentanamido]-3-methylbutanoic acid

C20H35N9O5 (481.27610200000004)

His Ala Val Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]propanamido]-3-methylbutanamido]-5-carbamimidamidopentanoic acid

C20H35N9O5 (481.27610200000004)

His Gly Ile Arg

(2S)-2-[(2S,3S)-2-{2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]acetamido}-3-methylpentanamido]-5-carbamimidamidopentanoic acid

C20H35N9O5 (481.27610200000004)

His Gly Leu Arg

(2S)-2-[(2S)-2-{2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]acetamido}-4-methylpentanamido]-5-carbamimidamidopentanoic acid

C20H35N9O5 (481.27610200000004)

His Gly Arg Ile

(2S,3S)-2-[(2S)-2-{2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]acetamido}-5-carbamimidamidopentanamido]-3-methylpentanoic acid

C20H35N9O5 (481.27610200000004)

His Gly Arg Leu

(2S)-2-[(2S)-2-{2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]acetamido}-5-carbamimidamidopentanamido]-4-methylpentanoic acid

C20H35N9O5 (481.27610200000004)

His Ile Gly Arg

(2S)-2-{2-[(2S,3S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-methylpentanamido]acetamido}-5-carbamimidamidopentanoic acid

C20H35N9O5 (481.27610200000004)

His Ile Asn Val

(2S)-2-[(2S)-2-[(2S,3S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-methylpentanamido]-3-carbamoylpropanamido]-3-methylbutanoic acid